9-ING-41

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Actuate 1801: Phase 1/2 Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

9-ING-41 in Patients With Advanced Cancers

Actuate 1901: 9-ING-41 in Myelofibrosis

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma